ReviewJournal of oncology2022
Sphingolipid Metabolism and Signaling in Lung Cancer: A Potential Therapeutic Target.
Review in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Harnessing Exhaled Breath for Lung Cancer Early Detection-Results From the ExPeL Study.Clinical and translational science · 2026Article
- Altered Sphingolipid Metabolism is Associated with Osimertinib Resistance in Nonsmall-Cell Lung Cancer.Journal of proteome research · 2026Article
- Lipidomic signatures as predictive biomarkers for early-onset lung cancer: Identification and development of a risk prediction model.Journal of advanced research · 2026Article
- Exploring and Validating Prognostic Biomarkers Related to Sphingolipid Metabolism in Gastric Cancer through Machine LearningEndocrine, metabolic & immune disorders drug targets · 2026Article
- CES3 promotes NSCLC progression via lipid metabolic reprogramming regulated by TFAP2A.Journal of Cancer · 2026Article
- Biomarkers for non-small cell lung cancer risk using multi-omics approaches: a nested case-control study.Translational lung cancer research · 2025Article
- Combined Serum IL-6 and CYFRA 21-1 as Potential Biomarkers for Radon-Associated Lung Cancer Risk: A Pilot Study.Biomedicines · 2025Article
- Exploring Exhaled Breath Analysis in Adults With Chronic Visceral Acid Sphingomyelinase Deficiency to Identify Potential Biomarkers of Pulmonary Involvement.Journal of inherited metabolic disease · 2025Article
- Machine Learning Unveils Sphingolipid Metabolism's Role in Tumour Microenvironment and Immunotherapy in Lung Cancer.Journal of cellular and molecular medicine · 2025Article
- Regulation of sphingolipid metabolism in the immune microenvironment of gastric cancer: current insights and future directions.Frontiers in oncology · 2025Review
- Article
- The Role of Sphingolipid Metabolism in Pregnancy-Associated Breast Cancer After Chemotherapy.Biomedicines · 2024Article
- Integrated bulk and single-cell profiling characterize sphingolipid metabolism in pancreatic cancer.BMC cancer · 2024Article
- Article
- Mechanism underlying the effect of MnOMikrochimica acta · 2023Article
- Lipid-lowering drugs affect lung cancer risk via sphingolipid metabolism: a drug-target Mendelian randomization study.Frontiers in genetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingolipids are important bioactive lipids that not only play an important role in maintaining the barrier function and fluidity of cell membranes but also regulate multiple processes in cancer development by controlling multiple signaling pathways in the signal transduction network. Dysregulation of sphingolipid metabolism is thought to be one of the most important dysregulated pathways in lung cancer, the most prevalent type of cancer in terms of incidence and mortality worldwide. This article focuses on lung cancer, reviewing the important lipids in sphingolipid metabolism and the related enzymes in relation to lung cancer progression and their effects on the tumor microenvironment and discussing their roles in the diagnosis and treatment of lung cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.